Bim-targeted cancer therapy: a link between drug action and underlying molecular changes
- PMID: 19934277
- DOI: 10.1158/1535-7163.MCT-09-0685
Bim-targeted cancer therapy: a link between drug action and underlying molecular changes
Abstract
In the past few years, the pro-apoptotic molecule Bim has attracted increasing attention as a plausible target for tumor therapy. A variety of normal and pathological systems regulated by Bim, dependent on cell type, apoptotic stimulation, and chemotherapeutic agents, have been documented. Bim promotes anoikis of many tumor cells, such as lung cancer, breast cancer, osteosarcoma, and melanoma. Various chemotherapeutic agents use Bim as a mediating executioner of cell death. Hence, Bim suppression supports metastasis and chemoresistance. Imatinib, gefitinib, bortezomib, and Bim protein itself are spotlighted as current and future Bim-targeting therapeutic agents. The potential benefits of Bim-targeted therapies are selectivity of treatment for tumor cells and reduction in tumor-associated phenomena such as chemoresistance and metastasis. Thus, Bim-targeting therapies may provide more effective and unique tumor management modalities in future. This review article discusses all these issues.
Similar articles
-
PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.Breast Cancer Res. 2015 Jun 19;17(1):86. doi: 10.1186/s13058-015-0594-z. Breast Cancer Res. 2015. PMID: 26084280 Free PMC article.
-
Bim(L) displacing Bcl-x(L) promotes Bax translocation during TNFalpha-induced apoptosis.Apoptosis. 2008 Jul;13(7):950-8. doi: 10.1007/s10495-008-0226-5. Epub 2008 May 24. Apoptosis. 2008. PMID: 18500555
-
Overexpression of BimSs3, the novel isoform of Bim, can trigger cell apoptosis by inducing cytochrome c release from mitochondria.Acta Biochim Pol. 2007;54(3):603-10. Epub 2007 Aug 24. Acta Biochim Pol. 2007. PMID: 17717606
-
BH3-only protein BIM: An emerging target in chemotherapy.Eur J Cell Biol. 2017 Dec;96(8):728-738. doi: 10.1016/j.ejcb.2017.09.002. Epub 2017 Sep 23. Eur J Cell Biol. 2017. PMID: 29100606 Review.
-
Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics.FEBS J. 2009 Nov;276(21):6050-62. doi: 10.1111/j.1742-4658.2009.07329.x. Epub 2009 Sep 29. FEBS J. 2009. PMID: 19788418 Review.
Cited by
-
Targeting Cdc20 as a novel cancer therapeutic strategy.Pharmacol Ther. 2015 Jul;151:141-51. doi: 10.1016/j.pharmthera.2015.04.002. Epub 2015 Apr 4. Pharmacol Ther. 2015. PMID: 25850036 Free PMC article. Review.
-
PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.Breast Cancer Res. 2015 Jun 19;17(1):86. doi: 10.1186/s13058-015-0594-z. Breast Cancer Res. 2015. PMID: 26084280 Free PMC article.
-
Targeting Degradation of EGFR through the Allosteric Site Leads to Cancer Cell Detachment-Promoted Death.Cancers (Basel). 2019 Aug 1;11(8):1094. doi: 10.3390/cancers11081094. Cancers (Basel). 2019. PMID: 31374910 Free PMC article.
-
Increased expression of the pro-apoptotic protein BIM, a mechanism for cAMP/protein kinase A (PKA)-induced apoptosis of immature T cells.J Biol Chem. 2011 Sep 23;286(38):33260-7. doi: 10.1074/jbc.M111.268979. Epub 2011 Aug 1. J Biol Chem. 2011. PMID: 21808067 Free PMC article.
-
Deregulated cell death and lymphocyte homeostasis cause premature lethality in mice lacking the BH3-only proteins Bim and Bmf.Blood. 2014 Apr 24;123(17):2652-62. doi: 10.1182/blood-2013-11-537217. Epub 2014 Mar 14. Blood. 2014. PMID: 24632712 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
